These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 25889635)

  • 21. Understanding the basis of I50V-induced affinity decrease in HIV-1 protease via molecular dynamics simulations using polarized force field.
    Duan R; Lazim R; Zhang D
    J Comput Chem; 2015 Sep; 36(25):1885-92. PubMed ID: 26198456
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cyclic HIV-1 protease inhibitors derived from mannitol: synthesis, inhibitory potencies, and computational predictions of binding affinities.
    Hultén J; Bonham NM; Nillroth U; Hansson T; Zuccarello G; Bouzide A; Aqvist J; Classon B; Danielson UH; Karlén A; Kvarnström I; Samuelsson B; Hallberg A
    J Med Chem; 1997 Mar; 40(6):885-97. PubMed ID: 9083477
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Resilience to resistance of HIV-1 protease inhibitors: profile of darunavir.
    Lefebvre E; Schiffer CA
    AIDS Rev; 2008; 10(3):131-42. PubMed ID: 18820715
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Absolute free energies of binding of peptide analogs to the HIV-1 protease from molecular dynamics simulations.
    Bartels C; Widmer A; Ehrhardt C
    J Comput Chem; 2005 Sep; 26(12):1294-305. PubMed ID: 15981257
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Structure-based design: synthesis and biological evaluation of a series of novel cycloamide-derived HIV-1 protease inhibitors.
    Ghosh AK; Swanson LM; Cho H; Leshchenko S; Hussain KA; Kay S; Walters DE; Koh Y; Mitsuya H
    J Med Chem; 2005 May; 48(10):3576-85. PubMed ID: 15887965
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Omuralide and vibralactone: differences in the proteasome- β-lactone-γ-lactam binding scaffold alter target preferences.
    List A; Zeiler E; Gallastegui N; Rusch M; Hedberg C; Sieber SA; Groll M
    Angew Chem Int Ed Engl; 2014 Jan; 53(2):571-4. PubMed ID: 24285701
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Combined experimental and theoretical study on hydrogen-bonded complexes between cyclic ketones, lactones, and lactams with 3,4-dinitrophenol.
    Esseffar M; El Firdoussi A; Bouab W; Abboud JL; Mó O; Yáñez M
    J Phys Chem A; 2009 Dec; 113(52):14711-7. PubMed ID: 19824667
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Identifying the molecular mechanics and binding dynamics characteristics of potent inhibitors to HIV-1 protease.
    Li D; Liu MS; Ji B; Hwang KC; Huang Y
    Chem Biol Drug Des; 2012 Sep; 80(3):440-54. PubMed ID: 22621379
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Structural insights into the South African HIV-1 subtype C protease: impact of hinge region dynamics and flap flexibility in drug resistance.
    Naicker P; Achilonu I; Fanucchi S; Fernandes M; Ibrahim MA; Dirr HW; Soliman ME; Sayed Y
    J Biomol Struct Dyn; 2013 Dec; 31(12):1370-80. PubMed ID: 23140382
    [TBL] [Abstract][Full Text] [Related]  

  • 30. HIV protease inhibitors: synthesis and activity of N-aryl-N'-hydroxyalkyl hydrazide pseudopeptides.
    Marastoni M; Baldisserotto A; Trapella C; McDonald J; Bortolotti F; Tomatis R
    Eur J Med Chem; 2005 May; 40(5):445-51. PubMed ID: 15893018
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of atomic charge, solvation, entropy, and ligand protonation state on MM-PB(GB)SA binding energies of HIV protease.
    Oehme DP; Brownlee RT; Wilson DJ
    J Comput Chem; 2012 Dec; 33(32):2566-80. PubMed ID: 22915442
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Beta-lactam compounds as apparently uncompetitive inhibitors of HIV-1 protease.
    Sperka T; Pitlik J; Bagossi P; Tözsér J
    Bioorg Med Chem Lett; 2005 Jun; 15(12):3086-90. PubMed ID: 15893929
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Design and synthesis of new potent C2-symmetric HIV-1 protease inhibitors. Use of L-mannaric acid as a peptidomimetic scaffold.
    Alterman M; Björsne M; Mühlman A; Classon B; Kvarnström I; Danielson H; Markgren PO; Nillroth U; Unge T; Hallberg A; Samuelsson B
    J Med Chem; 1998 Sep; 41(20):3782-92. PubMed ID: 9748353
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Accurate prediction of protonation state as a prerequisite for reliable MM-PB(GB)SA binding free energy calculations of HIV-1 protease inhibitors.
    Wittayanarakul K; Hannongbua S; Feig M
    J Comput Chem; 2008 Apr; 29(5):673-85. PubMed ID: 17849388
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Oleanolic Acid Derivatives as Potential Inhibitors of HIV-1 Protease.
    Medina-O'Donnell M; Rivas F; Reyes-Zurita FJ; Cano-Muñoz M; Martinez A; Lupiañez JA; Parra A
    J Nat Prod; 2019 Oct; 82(10):2886-2896. PubMed ID: 31617361
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Synthesis and NMR assignment of pentacycloundecane precursors of potential pharmaceutical agents.
    Onajole OK; Makatini MM; Govender P; Govender T; Maguire GE; Kruger HG
    Magn Reson Chem; 2010 Mar; 48(3):249-55. PubMed ID: 20084637
    [TBL] [Abstract][Full Text] [Related]  

  • 37. 3D-QSAR CoMFA/CoMSIA models based on theoretical active conformers of HOE/BAY-793 analogs derived from HIV-1 protease inhibitor complexes.
    da Cunha EF; Sippl W; de Castro Ramalho T; Ceva Antunes OA; de Alencastro RB; Albuquerque MG
    Eur J Med Chem; 2009 Nov; 44(11):4344-52. PubMed ID: 19616874
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A contribution to the drug resistance mechanism of darunavir, amprenavir, indinavir, and saquinavir complexes with HIV-1 protease due to flap mutation I50V: a systematic MM-PBSA and thermodynamic integration study.
    Leonis G; Steinbrecher T; Papadopoulos MG
    J Chem Inf Model; 2013 Aug; 53(8):2141-53. PubMed ID: 23834142
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Applications of 3-aminolactams: design, synthesis, and biological evaluation of a library of potential dimerisation inhibitors of HIV1-protease.
    Pinyol E; Frutos S; Grillo-Bosch D; Giralt E; Clotet B; Esté JA; Diez A
    Org Biomol Chem; 2012 Jun; 10(22):4348-54. PubMed ID: 22546925
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Could the FDA-approved anti-HIV PR inhibitors be promising anticancer agents? An answer from enhanced docking approach and molecular dynamics analyses.
    Arodola OA; Soliman ME
    Drug Des Devel Ther; 2015; 9():6055-65. PubMed ID: 26622167
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.